<DOC>
	<DOCNO>NCT02083380</DOCNO>
	<brief_summary>A randomised , double-blind single-dose study determine efficacy , safety , tolerability pharmacokinetics OZ439 ( artefenomel ) combination piperaquine ( PQP ) patient &gt; 0.5 year &lt; = 70 year age uncomplicated Plasmodium falciparum malaria Africa Asia ( Vietnam ) . Interim analysis futility plan . Adults child include progressive step-down age follow safety review independent safety monitor board ( ISMB ) . If study meet efficacy objective , inform dose set Phase III study .</brief_summary>
	<brief_title>Phase II Efficacy Study Artefenomel &amp; Piperaquine Adults &amp; Children With P. Falciparum Malaria .</brief_title>
	<detailed_description>A randomised , double-blind single-dose ( loose combination ) study target patient population child &gt; 0.5 year &lt; = 5 year age Africa patient age Asia ( &gt; 0.5 year &lt; = 70 year ) uncomplicated Plasmodium falciparum malaria . Patients &gt; 5 year Africa also recruit safety age step procedure . The underlying assumption child 5 year less Africa age Asia high probability lower immunity hence potentially require high drug exposure achieve efficacy hence study aim recruit 60-80 % African child &lt; = 5 year 18-36 % Asian patient ( define target population ) approximately 10 % African patient &gt; 5 year , Three OZ439/PQP treatment arm include patient &gt; = 35 kg ( 800mg OZ439 loose combination PQP dose either 640 , 960 , 1440 mg ) . Doses scale patient &lt; 35kg base weight achieve similar exposure patient &gt; = 35kg . The study test futility dose arm drop probability &gt; 30 % PCR-adjusted ACPR Day 28 ( ACPR28 ) less 90 % ( target efficacy study &gt; = 95 % ACPR28 ) . Only data patient Asia patient Africa patient &lt; 5 year include Interim analysis , although patient include final analysis . Interim analyse occur recruitment approximately 50 evaluable patient per dose cohort thereafter approximately every 25 patient . In separate process , safety OZ439/PQP treatment arm assess scheduled time point ISMB adult child include progressive step-down age range follow safety evaluation Following Screening informed consent , patient receive study drug follow clinical sign malaria ( parasitaemia temperature ) , safety assessment pharmacokinetics Day 42 follow dosing ( Day 63 select site ) .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>1 . Male female patient age &gt; 6 month &lt; 70 year . 2 . Body weight &gt; 5 kg &lt; 90 kg . 3 . Presence monoinfection P. falciparum : 1 . Fever , define axillary temperature ≥ 37.5°C oral/rectal/tympanic temperature ≥ 38°C , history fever previous 24 hour ( history fever must document ) , 2 . Microscopically confirm parasite infection , range 1,000 100,000 asexual parasite /µL blood . 4 . Written inform consent provide adult patient , parent legally acceptable representative ( LAR ) minor patient impartial witness ( patient patient 's LAR illiterate ) , medically qualified Investigator . Children ask provide assent appropriate . The age seek defined local legislation . 1 . Presence severe malaria ( accord World Health Organization ( WHO ) definition WHO 2013 ) 2 . Antimalarial treatment : 1 . With piperaquine base compound , mefloquine , naphthoquine sulphadoxine/pyrimethamine ( SP ) within previous 6 week ( inhibition new infection fall 50 % ) . 2 . With amodiaquine chloroquine within previous 4 week . 3 . With quinine , halofantrine , lumefantrinebased compound antimalarial treatment antibiotic antimalarial activity ( include cotrimoxazole , tetracycline , quinolones fluoroquinolones , azithromycin ) within past 14 day . 4 . With herbal product traditional medicine , within past 7 day . 3 . Known history evidence clinically significant disorder , respiratory ( include active tuberculosis ) , hepatic , renal , gastrointestinal , immunological , neurological ( include auditory ) , endocrine , infectious , malignancy , psychiatric , history convulsion abnormality ( include head trauma ) . 4 . Family history sudden death congenital clinical condition know prolong QTcB QTcF interval e.g . patient history symptomatic cardiac arrhythmia , clinically relevant bradycardia severe cardiac disease . 5 . History symptomatic cardiac arrhythmia clinically relevant bradycardia . 6 . Any predisposing cardiac condition arrhythmia severe hypertension , leave ventricular hypertrophy ( include hypertrophic cardiomyopathy ) congestive cardiac failure accompany reduce left ventricle ejection fraction . 7 . Electrolyte disturbance , particularly hypokalaemia , hypocalcaemia hypomagnesaemia . 8 . Any treatment induce lengthen QT interval , : 1 . Antiarrhythmics ( e.g . amiodarone , disopyramide , dofetilide , ibutilide , procainamide , quinidine , hydroquinidine , sotalol ) , 2 . Neuroleptics ( e.g . phenothiazine , sertindole , sultopride , chlorpromazine , haloperidol , mesoridazine , pimozide , thioridazine ) , 3 . Antidepressive agent , certain antimicrobial agent , include agent follow class macrolides ( e.g . erythromycin , clarithromycin ) , fluoroquinolones ( e.g . moxifloxacin , sparfloxacin ) , imidazole triazole antifungal agent , also pentamidine saquinavir , 4 . Certain nonsedating antihistamine ( e.g . terfenadine , astemizole , mizolastine ) , cisapride , droperidol , domperidone , bepridil , diphemanil , probucol , levomethadyl , methadone , vinca alkaloid , arsenic trioxide . 5 . Antiemetics know QT prolongation potential domperidone 9 . Mixed Plasmodium infection 10 . Severe vomiting , define three time 24 hour prior enrolment study inability tolerate oral treatment , severe diarrhoea define 3 watery stool per day 11 . Severe malnutrition ( defined subject age ten year less weightforheight 3 standard deviation less 70 % median National Centre Health Statistics ( NCHS ) /WHO normalised reference value , subject age great ten year , body mass index ( BMI ) less 16 ( WFP Manual , Chapter 1 ) ) . 12 . Known history hypersensitivity , allergic adverse reaction piperaquine aminoquinolones OZ439 OZ277 13 . Known active Hepatitis A IgM ( HAVIgM ) , Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody ( HCV Ab ) . 14 . If Total Bilirubin normal , exclude patient liver function test Aspartate transaminase ( AST ) / Alanine transaminase ( ALT ) ≥ 2x Upper limit normal ( ULN ) . 15 . If Total Bilirubin &gt; 1 ≤ 1.5xULN , exclude patient AST/ALT &gt; 1.5xULN . 16 . Total Bilirubin &gt; 1.5XULN 17 . Haemoglobin level 8 g/dL . 18 . Serum creatinine level ≥2 x ULN 19 . Female patient child bear potential must neither pregnant ( demonstrated negative pregnancy test ) lactating , must willing take measure become pregnant study period safety followup period . 20 . Have receive investigational drug within past 4 week . 21 . Previous participation malaria vaccine study receive malaria vaccine circumstance .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Plasmodium falciparum malaria</keyword>
	<keyword>malaria</keyword>
	<keyword>OZ439</keyword>
	<keyword>piperaquine</keyword>
	<keyword>PQP</keyword>
</DOC>